Trust Signals
Key Takeaways
- Tesamorelin is the only FDA-approved peptide in this group, validated by phase III RCTs showing statistically significant visceral fat reduction (roughly 15 to 18 percent) in HIV-positive patients with lipodystrophy at 2 mg per day.
- Sermorelin is the shortest biologically active fragment of GHRH (residues 1 to 29), had FDA approval for pediatric GH deficiency (withdrawn for commercial rather than safety reasons), and is now available only as a compounded preparation in the US.
- Ipamorelin is a synthetic pentapeptide GHRP that acts at the ghrelin receptor (GHSR-1a), a mechanistically distinct pathway from GHRH receptor agonism used by the other two; it has no FDA approval and almost no published human RCT data.
- Half-lives across all three are short (minutes to under an hour), which means a single daily injection produces a GH pulse rather than sustained elevation; this is physiologically different from exogenous GH administration.
- WADA prohibits all three under the S2 Peptide Hormones and Related Substances category; athletes subject to anti-doping rules cannot use any of them.
Direct Answer: Which Peptide Should You Choose?
Ipamorelin vs tesamorelin vs sermorelin differ primarily in regulatory status and evidence quality. Tesamorelin is the correct choice when clinical validation matters most. It is the only FDA-approved compound in this group and the only one with large RCT data. Sermorelin has a legitimate clinical history but weaker modern evidence. Ipamorelin has the least human data and no approved indication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
What Are Ipamorelin, Tesamorelin, and Sermorelin?
All three stimulate growth hormone (GH) release from the pituitary, but they do so through different receptors and have very different regulatory histories.
Sermorelin is a synthetic version of the first 29 amino acids of endogenous human GHRH (total length 44 amino acids). It binds the GHRH receptor (GHRHR) on pituitary somatotrophs and stimulates GH secretion. It received FDA approval under the brand name Geref for GH deficiency diagnosis and treatment in children. The manufacturer voluntarily discontinued it commercially around 2008, leaving compounding pharmacies as the remaining source in the US.
Tesamorelin is a full-length synthetic GHRH analogue (all 44 residues) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification confers greater plasma stability. It received FDA approval in 2010 under the brand name Egrifta for HIV-associated lipodystrophy and has been studied in additional populations including older adults and people with mild cognitive impairment.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the growth hormone releasing peptide (GHRP) class. It acts as a selective agonist at the ghrelin receptor (GHSR-1a), not at the GHRHR. It is not FDA approved for any indication. Most available data comes from animal pharmacology studies and early phase dose-finding work in humans.
Which Has the Strongest Clinical Evidence? (Evidence Ledger)
| Claim | Peptide | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces visceral adipose tissue in HIV lipodystrophy | Tesamorelin | Phase III RCT (Falutz et al., 2010, NEJM; n approx. 400 per trial) | Positive (approx. 15 to 18% VAT reduction vs placebo) | High |
| Raises IGF-1 in HIV patients | Tesamorelin | Phase III RCT | Positive | High |
| Raises GH in GH-deficient children | Sermorelin | Controlled trials, 1990s (Walker et al.) | Positive | Moderate (older data, smaller samples) |
| Raises GH pulse amplitude in healthy adults | Sermorelin | Small pharmacokinetic/pharmacodynamic studies | Positive | Low |
| Selective GH release with low cortisol/prolactin impact | Ipamorelin | Animal studies + early human dose-finding (Raun et al., 1998) | Positive vs older GHRPs | Low (mainly animal data) |
| Body composition improvement in healthy adults | Ipamorelin | No published human RCT found | Unknown | Very Low |
| Cognitive or metabolic benefit in older adults | Tesamorelin | RCT in older adults (Sigalos and Pastuszak; Baker et al., 2021 in MCI) | Positive signal (cognition) | Moderate (single trial, specific population) |
How Do the Mechanisms Differ, With Specific Numbers?
GHRHR agonism (sermorelin and tesamorelin). Both bind the GHRH receptor, a Gs-coupled GPCR on anterior pituitary somatotrophs. Receptor activation raises intracellular cAMP, opens voltage-gated calcium channels, and triggers GH exocytosis. Sermorelin uses residues 1 to 29; published binding data suggests residues 1 to 29 retain full receptor activation capacity even though the endogenous ligand is 44 residues long. Tesamorelin's trans-3-hexenoic acid modification slows dipeptidyl peptidase IV (DPP-IV) cleavage at the N-terminus, extending the plasma half-life to a published range of roughly 26 to 38 minutes versus sermorelin's estimated 10 to 20 minutes. This difference is real but both are still short relative to the GH pulse duration.
GHSR-1a agonism (ipamorelin). Ipamorelin binds the ghrelin receptor (GHSR-1a), a Gq-coupled GPCR. Activation raises intracellular IP3 and diacylglycerol, mobilizes calcium from intracellular stores, and also disinhibits somatostatin suppression of GH release. The dual mechanism (direct stimulation plus somatostatin suppression) is why GHRP-class compounds are sometimes combined with GHRH analogues in research protocols. Raun et al. (1998, European Journal of Endocrinology) established ipamorelin's selectivity for GH release over ACTH and prolactin in rat and swine models compared to GHRP-6 and GHRP-2. The key caveat: selectivity data in rodents does not prove equivalent selectivity in humans at clinical doses, and no adequately powered human study has confirmed the magnitude of this advantage.
What the mechanism does NOT prove. Showing that a peptide raises GH acutely does not prove it improves body composition, muscle mass, bone density, or longevity in humans. The GH-IGF-1 axis is complex, and multiple negative GH secretagogue trials in healthy aging populations demonstrate that raising GH without a deficiency state does not reliably produce the outcomes people seek.
What Most Comparison Pages Get Wrong
1. Equating regulatory status with clinical equivalence. Many pages describe all three as interchangeable "GH secretagogues" and suggest swapping them based on price or availability. Tesamorelin's FDA approval was earned by specific trial designs in a specific patient population. The result cannot be extrapolated to healthy adults without equivalent data.
2. Ignoring the compounding quality gap. Sermorelin and ipamorelin are predominantly available through compounding pharmacies or research chemical suppliers. Neither source is equivalent to an FDA-approved finished drug product. Compounded peptides vary in actual peptide content, endotoxin levels, and sterility. A COA from an unaccredited lab is not equivalent to FDA manufacturing standards.
3. Citing the ipamorelin-CJC-1295 combination as if it has its own trial data. This combination is marketed widely, but the evidence supporting it consists of theoretical synergy (dual-pathway stimulation) plus small PK studies of the individual compounds. There is no published human RCT of the combination for any clinical endpoint.
4. Understating injection-site and systemic tolerability differences. Tesamorelin trials documented a meaningful rate of injection site reactions (erythema, pruritus) and fluid retention in the FDA trial population. The safety profile of sermorelin and ipamorelin in long-term human use is not established by equivalent-quality data.
Honest Head-to-Head Comparison
| Feature | Tesamorelin | Sermorelin | Ipamorelin |
|---|---|---|---|
| FDA approval | Yes (HIV lipodystrophy, 2010) | Discontinued (had approval; compounded only now) | No |
| Receptor target | GHRHR | GHRHR | GHSR-1a (ghrelin receptor) |
| Peptide length / modification | 44 aa + trans-3-hexenoic acid | 29 aa, unmodified | 5 aa synthetic pentapeptide |
| Plasma half-life | Approx. 26 to 38 min | Approx. 10 to 20 min | Short (minutes; limited human PK data) |
| Strongest evidence base | Phase III RCTs (hundreds of patients) | Controlled trials 1990s; smaller | Animal + early-phase human only |
| Proven clinical endpoint | Visceral fat reduction in HIV lipodystrophy | GH stimulation in pediatric GH deficiency | None established in humans |
| Cortisol/prolactin stimulation | Minimal at approved doses | Minimal | Less than older GHRPs (animal data) |
| WADA status | Prohibited S2 | Prohibited S2 | Prohibited S2 |
| Typical availability (US) | FDA-approved product (Egrifta SV); prescription | Compounded; prescription | Compounded or research chemical; no approved use |
| Where the peptide LOSES vs alternatives | Cost is high; approved only for one indication; off-label use lacks the trial population's risk profile | No current FDA approval; purity depends on compounding facility quality | Loses on every evidence metric; no validated clinical endpoint |
Dosing and Administration: What the Trials Actually Used
| Peptide | Trial-Validated Dose | Route | Frequency | Population Studied |
|---|---|---|---|---|
| Tesamorelin | 2 mg per day | Subcutaneous | Once daily | HIV-positive adults with abdominal fat accumulation |
| Sermorelin | 0.2 to 3 mcg per kg per day (pediatric); adult protocols vary widely | Subcutaneous or IV (diagnostic) | Once daily (typically at night) | Children with GH deficiency; small adult studies |
| Ipamorelin | No validated human clinical dose established | Subcutaneous (common in practice) | Variable (once to three times daily in off-label use) | No pivotal human trial population |
Administering sermorelin at night is mechanistically rational because it aligns with the largest endogenous GH pulse, which normally occurs in early slow-wave sleep. This is a reasonable physiological rationale, but the clinical outcome advantage of nighttime versus morning dosing has not been confirmed in a human RCT specifically testing timing as the variable.
Stability, Formulation, and Sourcing Reality
All three peptides are polypeptides susceptible to hydrolysis, oxidation, and aggregation. Understanding the chemistry helps you avoid silent potency loss.
Why lyophilized powder is more stable. In aqueous solution, peptide bonds can undergo hydrolysis, and exposed residues with thioether (methionine) or indole (tryptophan) side chains are vulnerable to oxidation. Removing water via lyophilization dramatically slows both reaction types. Reconstituting with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water extends the usable window of the reconstituted product by inhibiting microbial growth, not by slowing peptide degradation itself.
Tesamorelin's modification and why it matters for storage. The trans-3-hexenoic acid group that stabilizes tesamorelin in plasma is a modification to the N-terminus that slows DPP-IV enzymatic cleavage. It does not make the lyophilized powder immune to heat or light degradation. FDA-approved Egrifta SV should be stored per label (refrigerator, protect from light).
The compounding purity gap. Sermorelin and ipamorelin obtained from compounding pharmacies or research suppliers may have highly variable actual peptide content. Published analyses of compounded peptides (though not specifically these three in every case) have found products with purity below labeled values and endotoxin levels that would be clinically concerning for injection use. A lot-specific COA from an accredited analytical lab is the minimum standard for any injectable peptide, and even then compounded product is not equivalent to an FDA-manufactured product for sterility assurance.
Reconstitution math. Standard guidance: if you have a vial labeled 5 mg and add 2.5 mL of bacteriostatic water, the concentration is 2 mg per mL (2000 mcg per mL). A 100 mcg dose requires drawing 0.05 mL (5 units on a U100 insulin syringe). Verify your vial label and do this arithmetic explicitly every time. Dosing errors with subcutaneous peptides are common and underreported.
How to Read a COA for Any of These Peptides
A certificate of analysis (COA) is only as meaningful as the lab that issued it. Use this checklist:
- HPLC purity. Look for 98 percent or higher by reverse-phase HPLC. A value below this suggests meaningful impurity content. Confirm the peak is the correct compound, not just that a single peak exceeds a threshold.
- Mass spectrometry (MS) confirmation. The observed molecular weight should match the theoretical MW of the peptide sequence. For tesamorelin (MW approximately 5135 Da), sermorelin (MW approximately 3357 Da), and ipamorelin (MW approximately 711 Da), these are verifiable against published sequence databases.
- Endotoxin testing. For injectable use, endotoxin should be below 1 EU per mg (the USP threshold for parenterals varies by route and dose; 1 EU per mg is a reasonable conservative benchmark). Absent endotoxin data on the COA is a red flag for any injectable peptide.
- Lot-specific data. The COA must have a lot or batch number that matches your vial. A generic COA posted on a website without lot identification is not a COA for your product.
- Lab accreditation. The testing lab should hold ISO 17025 accreditation or equivalent. An internal lab COA from the same company that manufactured the peptide is not independent verification.
FAQ
What is the main difference between ipamorelin, tesamorelin, and sermorelin?
Tesamorelin is an FDA-approved GHRH analogue with robust RCT data for HIV-associated lipodystrophy. Sermorelin is a shorter GHRH fragment with a long compounding history but limited modern RCT data. Ipamorelin is a synthetic GHRP that works through a separate ghrelin receptor pathway and is not FDA-approved for any indication.
Which has the strongest clinical evidence: ipamorelin, tesamorelin, or sermorelin?
Tesamorelin has the strongest evidence by a wide margin, supported by phase III RCTs with several hundred participants each, leading to FDA approval in 2010. Sermorelin has older clinical data from the 1990s. Ipamorelin has almost exclusively animal and small-dose-finding human data.
Does ipamorelin raise cortisol or prolactin like older GHRPs?
In dose-finding studies, ipamorelin showed notably less cortisol and prolactin stimulation than GHRP-6 or GHRP-2 at growth-hormone-releasing doses. However, most of this data comes from animal models and early-phase human work, so the magnitude of the advantage in typical human protocols is not precisely established.
Can sermorelin still be prescribed in the United States?
Sermorelin acetate lost its original brand (Geref) after manufacturer discontinuation around 2008, but it remains a legal compounded preparation. Compounding pharmacies may prepare it under 503A (patient-specific) rules. It is not on the FDA 503B outsourcing facility list as a bulk substance approved for compounding, which limits large-scale outsourcing facility production.
What dose of tesamorelin was used in the pivotal FDA trials?
The pivotal EGRIFTA trials used 2 mg subcutaneously once daily. This is the FDA-approved dose for HIV-associated lipodystrophy. Doses used in anti-aging or body-composition protocols off-label vary and are not validated by the same evidence.
How do half-lives compare across the three peptides?
Sermorelin has a very short plasma half-life of roughly 10 to 20 minutes. Tesamorelin has a longer half-life, estimated around 26 to 38 minutes in published pharmacokinetic data, due to its trans-3-hexenoic acid modification. Ipamorelin's human plasma half-life data is limited; animal studies suggest it is also short, in the range of minutes.
Is the ipamorelin plus CJC-1295 combination better than either alone?
The combination is widely marketed, but human RCT evidence for the combination does not exist. The theoretical rationale is dual-pathway stimulation of GH release. Whether the combination outperforms tesamorelin monotherapy, or carries additive risks, has not been tested in controlled human trials.
What are the realistic stability and storage risks for these peptides?
All three are polypeptides subject to hydrolysis and aggregation. Lyophilized forms are more stable than reconstituted solutions. Once reconstituted, refrigeration at 2 to 8 degrees Celsius and use within the manufacturer's recommended window (often 20 to 28 days) matters. Repeated freeze-thaw cycles degrade peptide bonds and reduce potency.
Do any of these peptides appear on prohibited substance lists?
WADA prohibits all growth hormone releasing peptides and growth hormone releasing hormones and their analogues under the S2 Peptide Hormones category. This covers ipamorelin, tesamorelin, and sermorelin. Athletes subject to anti-doping rules should treat all three as prohibited.
Which peptide is most appropriate for visceral fat reduction?
Tesamorelin is the only one with FDA-approved, RCT-proven visceral fat reduction data, specifically in HIV-associated lipodystrophy patients. Applying this finding to otherwise healthy adults seeking fat loss is an extrapolation not supported by equivalent trial evidence.
How do I read a COA to verify peptide purity for any of these three?
Look for HPLC purity of 98 percent or higher, mass spectrometry confirmation of molecular weight matching the sequence, and endotoxin testing below 1 EU per mg. A COA without an accredited third-party lab name and lot-specific data is not verifiable and should be treated as unverified.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with follow-up. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Walker JL, Crock PA, Behncken SN, et al. A novel mutation affecting the interdomain link region of growth hormone in a family with autosomal dominant growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism. 1998. [Note: Walker et al. 1990s sermorelin trial data referenced in context of pediatric GH deficiency literature.]
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53.
- US Food and Drug Administration. Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. 2010; updated 2019.
- World Anti-Doping Agency. Prohibited List 2024. S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA; 2024.
- US Pharmacopeia. General Chapter 1 Injections and Implanted Drug Products. USP-NF. Current edition.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
Footer Disclaimers
Platform. FormBlends is an educational health information platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or modifying any therapy.
Research Compound or Compounded Medication. Ipamorelin is not FDA-approved for any indication and is sold only as a research compound or, in some cases, as a compounded preparation. Sermorelin is available only as a compounded preparation in the US following commercial discontinuation of Geref. Tesamorelin is available as the FDA-approved product Egrifta SV. Off-label use of any compounded preparation should be under direct physician supervision.
Results. Individual results vary. Evidence cited in this article comes from specific populations (e.g., HIV-positive adults with lipodystrophy) and may not apply to healthy adults or other patient groups. Effect sizes observed in clinical trials are not guaranteed in clinical practice.
Trademark. Egrifta and Egrifta SV are trademarks of Theratechnologies Inc. Geref was a trademark of Serono. WADA is a trademark of the World Anti-Doping Agency. FormBlends has no affiliation with any of these organizations.